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Recent findings have implicated gp130 receptor ligands, particularly ciliary neurotrophic factor (CNTF), as potential antiobesity therapeutics. Neuropoietin (NP) is a recently discovered
cytokine in the gp130 family that shares functional and structural features with CNTF and signals via the CNTF receptor
tripartite complex comprised of CNTFR␣, LIF receptor, and
gp130. NP plays a role in the development of the nervous system,
but the effects of NP on adipocytes have not been previously
examined. Because CNTF exerts anti-obesogenic effects in adipocytes and NP shares the same receptor complex, we investigated the effects of NP on adipocyte development and insulin
action. Using cultured 3T3-L1 adipocytes, we observed that NP
has the ability to block adipogenesis in a dose- and time-dependent manner. We also observed that cultured adipocytes, as well
as murine adipose tissue, are highly responsive to acute NP
treatment. Rodents injected with NP had a substantial increase
in STAT3 tyrosine phosphorylation and ERK 1 and 2 activation.
We also observed the induction of SOCS-3 mRNA in 3T3-L1
adipocytes following NP treatment. Unlike CNTF, our studies
have revealed that NP also substantially attenuates insulin-stimulated glucose uptake in 3T3-L1 adipocytes. In addition, NP
blocks insulin action in adipose tissue in vivo. These observations are supported by data demonstrating that NP impairs
insulin signaling via decreased activation of both IRS-1 and Akt.
In summary, we have observed that both adipocytes in vitro and
in vivo are highly responsive to NP, and this cytokine has the
ability to affect insulin signaling in fat cells. These novel observations suggest that NP, unlike CNTF, may not be a viable obesity therapeutic.

In recent years, gp130 receptor ligands, notably ciliary neurotrophic factor (CNTF),2 have been implicated as potential
targets for obesity therapeutics (reviewed in Ref. 1). It is well
known that obese individuals are usually leptin-resistant,
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despite increased production of endogenous leptin (2, 3).
Hence, leptin is not a viable cytokine therapeutic. Therefore,
the characterization of cytokine-mediated anti-obesity mechanisms that act independently of leptin may be utilized for the
treatment of obesity. Because gp130 and leptin receptor (LR␤)
possess substantial sequence homology (4, 5) and both activate
the JAK/STAT pathway (6) and other signal transduction pathways that are important in energy balance (7–10), gp130 cytokines may provide a mechanism to evade leptin resistance. Also,
recent studies have shown that CNTF can have anti-obesogenic
effects in both high fat diet induced and db/db mice (11), indicating that the effects of CNTF are not dependent on a functional leptin receptor. In addition, leptin does not stimulate the
tyrosine phosphorylation of gp130 to activate the JAK/STAT
pathway (12). These data suggest that neither gp130 nor LR␤
signal through each others ligand. Likewise, the efficacy of the
gp130 cytokine as a therapeutic would not be altered because of
the leptin-resistant phenotype.
CNTF was originally characterized through its ability to
maintain the survival of parasympathetic and motor neurons
(reviewed in Ref. 13). The anti-obesogenic properties of CNTF
were discovered in clinical trials examining its effects on progression of the neurodegenerative disease amyotrophic lateral
sclerosis (14). This observation led to many studies to understand the effects of CNTF on weight loss. Early studies revealed
that the CNTF receptors and LR␤ were colocalized in the hypothalamus, and CNTF administration activated or suppressed
the same genes as leptin in the arcuate nucleus (15). These
studies suggested similar roles for these cytokines in neuronal
signaling pathways that affect satiety. Also, CNTF treatment of
leptin-deficient ob/ob and leptin-resistant db/db mice as well as
mice with diet-induced obesity and partial resistance to leptin
was found to reduce adiposity, hyperphagia, and hyperinsulinemia (15). Subsequent studies revealed that Axokine, a human
recombinant form of CNTF, also improved the phenotype of
obese, leptin-resistant rodents (16). Collectively, these studies
provide evidence to support the use of gp130 cytokines, specifically CNTF, as potential obesity therapeutics.
Though all gp130 cytokines share the transmembrane protein gp130 as a transducer in their receptor complex (reviewed
in Ref. 17), the other components of each respective complex
are variable. Interleukin-6 (IL-6) and interleukin-11 (IL-11)
first bind to IL-6 receptor ␣ and IL-11 receptor ␣, respectively,
and then recruit a gp130 homodimer complex for signaling.
Interleukin-27 (IL-27) engages a gp130/WSX-1 heterodimeric
receptor complex (18). Leukemia inhibitory factor (LIF) and
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oncostatin M (OSM) directly bind the gp130/LIF receptor
(LIFR) complex to induce signal transduction; OSM can alternatively utilize a gp130/OSM receptor (OSMR) complex. Cardiotrophin-1 (CT-1) recruits an ␣-receptor (19), which to date
has not been characterized, and also signals via gp130/LIFR.
CNTF, cardiotrophin-like cytokine (CLC), and neuropoietin
(NP) all recruit CNTFR␣ and then induce the formation of a
gp130/LIFR heterodimer for signal transduction (20 –22). The
requirement of NP to utilize CNTF signaling receptors was supported by studies which showed that NP did not signal in cells
expressing only LIFR and gp130, but not CNTFR␣ (22).
CNTF-deficient mice develop normally and exhibit only a
mild loss of motor neurons later in adulthood (23), whereas
newborn mice lacking CNTFR␣ display a dramatic loss of
motor neurons, fail to initiate the feeding process, and die
shortly after birth (24). These studies provided evidence for the
existence of an alternative ligand for the CNTF receptor complex, which led to the initial characterization of NP, a 22-kDa
member of the gp130 cytokine family (22). Though not
detected in adult tissues, NP is expressed in embryonic mouse
neuroepithelia at a time during development when both CNTF
and CLC are absent (22). NP, like CNTF, can also mediate
motor neuron survival (22). Importantly, the actions of NP are
dependent on the presence of the tripartite functional receptor
complex for CNTF that includes CNTFR␣, LIFR, and gp130
(20, 22). Because of the functional similarities between NP and
CNTF and their utilization of the same tripartite receptor complex, we hypothesized that NP might mimic the anti-obesogenic properties of CNTF. We have previously shown that
CNTF treatment induces STAT3 activation in adipocytes in
vitro and in vivo and that CNTFR␣ is expressed in adipose tissue and regulated in obese/type II diabetic rats (25).
Because CNTF induces weight loss (14 –16) and does not
result in the development of insulin resistance in adipocytes
(25) and NP utilizes the same tripartite receptor complex as
CNTF (22), we examined the ability of NP to modulate adipocyte differentiation and insulin action. Although the roles of NP
in the nervous system have been examined, the effects of NP on
adipocytes have not been studied. Our results demonstrate that
both 3T3-L1 adipocytes and rat adipose tissue are responsive to
NP treatment. Our studies also indicate that NP specifically
activates STAT3 Tyr705 in vivo and in vitro. We also observed
the induction of SOCS-3 mRNA in 3T3-L1 adipocytes and
MAPK (ERK 1 and 2) activation in vivo following NP treatment.
In addition, our studies demonstrate that NP can inhibit adipogenesis and negatively affect insulin signaling in cultured adipocytes. Overall, our findings indicate that adipocytes are
highly responsive to NP. However, unlike CNTF, our results
indicate that NP is not a suitable anti-obesity therapeutic,
because it inhibits insulin action in adipocytes.

EXPERIMENTAL PROCEDURES
Materials—Dulbecco’s Modified Eagle’s Medium (DMEM)
was purchased from Sigma. Bovine and fetal bovine sera were
purchased from Atlanta Biological. Mouse recombinant NP,
mouse recombinant CT-1, mouse recombinant OSM, and rat
recombinant CNTF were all purchased from R&D Systems.
Mouse recombinant LIF was purchased from BD Transduction.
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GH (porcine) and insulin (bovine) were purchased from Sigma.
STAT1 and STAT5A were polyclonal IgGs purchased from
Santa Cruz Biotechnology. STAT3 was a monoclonal IgG purchased from BD Transduction. The phosphospecific monoclonal antibody for STAT3 (Tyr705) was purchased from BD
Transduction. The highly phosphospecific polyclonal antibodies for IRS1 (Tyr896) and Akt (Ser473) were purchased from BIOSOURCE and Cell Signaling, respectively. The ERK polyclonal
antibody and the PPAR␥ monoclonal antibody were both purchased from Santa Cruz Biotechnology. The polyclonal active
MAPK antibody was purchased from Promega. Adiponectin
polyclonal antibody was purchased from Affinity Bioreagents.
DNase I and TRIzol were both purchased from Invitrogen.
Nitrocellulose and Zeta Probe-GT membranes were purchased
from Bio-Rad. The BCA kit and the enhanced chemiluminescence kit were purchased form Pierce. Horseradish peroxidaseconjugated secondary antibodies were purchased from Jackson
ImmunoResearch Laboratories.
Cell Culture—Murine 3T3-L1 preadipocytes were plated and
grown to 2-day post-confluence in DMEM containing 10%
bovine serum. Medium was changed every 48 h. Cells were
induced to differentiate by changing the medium to DMEM
containing 10% fetal bovine serum, 0.5 mM 3-isobutylmethylxanthine, 1 M dexamethasone, and 1.7 M insulin (MDI). After
48 h, this medium was replaced with DMEM supplemented
with 10% fetal bovine serum, and cells were maintained in this
medium until utilized for experimentation. In some experiments, cells were induced to differentiate in the presence of NP
and treated at various times after the addition of the differentiation mixture.
Preparation of Whole Cell Extracts—Cell monolayers of
3T3-L1 adipocytes were harvested in a non-denaturing buffer
containing 150 mM NaCl, 10 mM Tris, pH 7.4, 1 mM EGTA, 1
mM EDTA, 1% Triton X-100, 0.5% Igepal CA-630, 1 M phenylmethylsulfonyl fluoride, 1 M pepstatin, 50 trypsin inhibitory
milliunits of aprotinin, 10 M leupeptin, and 2 mM sodium vanadate, and frozen. Next, the samples were thawed and centrifuged at 13,000 rpm at 4 °C for 10 min. Supernatants containing
whole cell extracts were analyzed for protein content using a
BCA kit according to the manufacturer’s instructions.
Preparation of Nuclear and Cytosolic Extracts—Untreated
and NP-treated serum-deprived 3T3-L1 adipocytes were harvested in a nuclear homogenization buffer containing 20 mM
Tris (pH 7.4), 10 mM NaCl, and 3 mM MgCl2. Igepal CA-630 was
added to a final concentration of 0.15%, and cells were homogenized with 16 strokes in a Dounce homogenizer. The homogenates were centrifuged at 3500 rpm for 8 min. Supernatants
were saved as cytosolic extract, and the nuclear pellets were
resuspended in half the volume of nuclear homogenization
buffer and were centrifuged as before. The pellet was then
resuspended in an extraction buffer containing 20 mM HEPES
(pH 7.9), 420 mM NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, and 25%
glycerol. Both cytosolic and nuclear samples were frozen until
time for analysis and later thawed at room temperature. 200
units of DNase I were added to each nuclear sample, and the
tubes were inverted and incubated an additional 10 min at
room temperature. Finally, the samples were subjected to centrifugation at 13,000 rpm at 4 °C for 10 min. Cytosolic fractions
VOLUME 283 • NUMBER 33 • AUGUST 15, 2008
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and supernatants containing nuclear extracts were analyzed for
protein content using a BCA kit (Pierce).
Rodent Adipose Tissue Isolation—Animals were euthanized
by cervical dislocation, and tissues were immediately removed
and frozen in liquid nitrogen. Frozen tissues were homogenized
in a buffer containing 150 mM NaCl, 10 mM Tris, pH 7.4, 1 mM
EGTA, 1 mM EDTA, 1% Triton X-100, 0.5% Igepal CA-630, 1
M phenylmethylsulfonyl fluoride, 1 M pepstatin, and 50 trypsin inhibitory milliunits of aprotinin, 10 M leupeptin, and 2
mM sodium vanadate. Homogenates were centrifuged for 10
min at 5,000 rpm to remove any debris and insoluble material
and then analyzed for protein content. All animal studies were
carried out with protocols which were reviewed and approved
by institutional animal care and use committees.
Gel Electrophoresis and Western Blot Analysis—Proteins
were separated in 7.5% polyacrylamide (acrylamide from
National Diagnostics) gels containing SDS according to Laemmli (26) and transferred to nitrocellulose membrane in 25 mM
Tris, 192 mM glycine, and 20% methanol. Following transfer,
the membrane was blocked overnight in 4% milk at 4 °C. Results
were visualized with horseradish peroxidase-conjugated secondary antibodies and enhanced chemiluminescence.
RNA Analysis—Total RNA was isolated from cell monolayers with TRIzol according to the manufacturer’s instructions
with minor modifications. For Northern blot analysis, 20 g of
total RNA was denatured in formamide and electrophoresed
through a formaldehyde/agarose gel. The RNA was transferred
to Zeta Probe-GT, cross-linked, hybridized, and washed as previously described (27). Probes were labeled by random priming
using Klenow fragment and [␣ 32P]dATP.
Determination of 3H-labeled 2-Deoxyglucose Uptake—The
assay of 2- [3H]deoxyglucose was performed as previously
described (28). Prior to the assay, mature 3T3-L1 adipocytes
were serum-deprived for 2 h and then incubated in the presence
or absence of insulin (50 nM) for 10 min and the presence or
absence of NP for 6 h. Glucose uptake was initiated by addition
of 2- [3H]deoxyglucose at a concentration of 0.1 mM 2-deoxyglucose in 1 Ci of 2-[3H]deoxyglucose in Krebs-Ringer-Hepes
buffer and incubated for 3 min at room temperature. Glucose
uptake is reported as [3H]radioactivity, corrected for nonspecific diffusion (5 M cytochalasin B) and normalized to total
protein content as determined by BCA analysis. Nonspecific
uptake and absorption was always less than 10% of the total
uptake. Uptake measurements were performed in triplicate
under conditions where hexose uptake was linear.

RESULTS
To determine if adipocytes were responsive to NP, we examined the ability of this gp130 cytokine to activate STAT proteins
in adipocytes. Fully differentiated 3T3-L1 adipocytes were
treated with several different gp130 cytokines including CT-1,
LIF, OSM, and NP for 10 min. As shown in Fig. 1, NP-activated
STAT3 Tyr705 phosphorylation in a manner equivalent to
CT-1, LIF, and OSM. Because growth hormone (GH) is not a
gp130 cytokine and is not a potent activator of STAT3 tyrosine
phosphorylation in these cells (29), this growth factor was used
as a negative control. The levels of STAT3 protein were equivalent in each sample.
AUGUST 15, 2008 • VOLUME 283 • NUMBER 33

FIGURE 1. Neuropoietin activates STAT3 as potently as other gp130 cytokines. Fully differentiated 3T3-L1 adipocytes were treated for 10 min with
either CT-1(1 nM), LIF (1 nM), OSM (1 nM), NP (1 nM), or GH (0.5 nM). Following
treatment, whole cell extracts were prepared, and 150 g of each extract
were separated by SDS-PAGE, transferred to nitrocellulose, and subjected to
Western blot analysis. The detection system was horseradish peroxidase-conjugated secondary antibodies and enhanced chemiluminescence. This is a
representative experiment independently performed three times.

FIGURE 2. Neuropoietin activates STAT3 in a dose-dependent manner
and induces the translocation of STAT3 to the nucleus. A, fully differentiated 3T3-L1 adipocytes were treated for 10 min with the various doses of NP
or insulin (50 nM). Following treatment, whole cell extracts were prepared,
and 150 g of each extract were separated by SDS-PAGE, transferred to nitrocellulose, and subjected to Western blot analysis. B, cytosolic and nuclear
extracts were prepared from fully differentiated 3T3-L1 adipocytes following
a treatment with 1 nM NP for the times indicated. 150 g of each extract were
separated by SDS-PAGE, transferred to nitrocellulose, and subjected to Western blot analysis. Each figure represents an experiment independently performed three times.

To investigate the specificity of NP action in adipocytes,
serum-deprived fully differentiated 3T3-L1 adipocytes were
treated with various doses of NP (0.12, 0.25, 0.5, 1, 2, and 2.5 nM)
or insulin for 10 min. Although we detected low levels of
STAT3 activation with 0.25 and 0.5 nM NP, we observed substantial activation with 1, 2, and 2.5 nM NP treatments (Fig. 2A).
These results indicate that NP activated STAT3 Tyr705 in a
dose-dependent manner, with maximal activation at 1 nM.
Because insulin induces the serine, but not the tyrosine, phosphorylation of STAT3 (29, 30), this peptide hormone was used
as a negative control. ERK (MAPK) protein levels are shown to
demonstrate even loading.
Previous studies have demonstrated that, in addition to
STAT3, STATs 1, 5A, 5B, and 6 are expressed in both cultured
and native adipocytes (31). Therefore, we examined the ability
JOURNAL OF BIOLOGICAL CHEMISTRY
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FIGURE 3. Neuropoietin induces SOCS-3 mRNA. Fully differentiated 3T3-L1
adipocytes were treated with 1 nM NP for the times indicated. Following treatment, total RNA was collected from cells, and 20 g of each total RNA were
electrophoresed, transferred to nylon, and subjected to Northern blot analysis. This is a representative experiment independently performed three times.

of NP to activate other adipocyte-expressed STATs. Fully differentiated 3T3-L1 adipocytes were treated with NP for different times, ranging from 0.3 to 5 h. The cells were homogenized
and fractionated into nuclear and cytosolic extracts. The activation of STATs was observed by examining the presence of
these proteins in the nucleus. Based on the results in Fig. 2B, NP
did not activate STATs 1 and 5A, as the levels of these STATs in
the nucleus of NP-treated cells were similar to untreated control cells. In contrast, we observed a robust time-dependent
activation and nuclear translocation of STAT3.
Because various members of the gp130 cytokine family are
known to induce Suppressors of Cytokine Signaling (SOCS)-3
(32), we examined the ability of NP to induce SOCS-3 expression in fully differentiated 3T3-L1 adipocytes. As shown in Fig.
3, NP treatment resulted in a transient induction of SOCS-3
mRNA that was detectable at 30 min, and maximum expression
occurred after a 1-h treatment. Both aP2 and ␤-actin mRNA
levels were unaffected by the NP treatments. Ribosomal RNAs
are shown to demonstrate even loading of total RNA.
The data in Figs. 1–3 clearly indicated that NP activates
STAT3 and SOCS-3 in adipocytes in vitro; hence, we wanted to
determine if adipocytes in vivo were responsive to NP. SpragueDawley rats were injected with either NP (.20 g/g animal) or
vehicle (saline) and then sacrificed 15 min following the injection. As shown in Fig. 4, NP injection induced the activation of
STAT3 Tyr705 in both the epididymal and retroperitoneal adipose tissues, but not in skeletal muscle. NP also induced the
activation of MAPK (ERK 1 and 2) in adipose tissue, but not
skeletal muscle. The inability of NP to induce STAT3 tyrosine
phosphorylation in skeletal muscle was not caused by
decreased levels of STAT3 expression.
Because gp130 cytokines have been reported to have differential effects on adipogenesis (33–35), we investigated the ability of NP to modulate adipocyte differentiation. As shown in
Fig. 5A, 3T3-L1 preadipocytes were induced to differentiate in
the presence or absence of exogenously added NP, and whole
cell extracts were harvested at the indicated time points. Adipogenesis was assessed by examining the induction of PPAR␥
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FIGURE 4. Neuropoietin induces STAT3 tyrosine phosphorylation in adipose tissue in vivo. 6-week-old male Sprague-Dawley rats were given an
intraperitoneal injection of NP (0.20 g/g animal) or vehicle (saline) control. In
each individual experiment, at least two animals were used for each condition. 15 minutes after injection, rats were sacrificed, and both retroperitoneal
and epididymal fat pads and skeletal muscle tissues were immediately
removed and frozen in liquid nitrogen. 250 g of each tissue extract were
separated by SDS-PAGE, transferred to nitrocellulose, and subjected to Western blot analysis. This is a representative experiment independently performed three times.

and adiponectin. NP attenuated adipogenesis, as evidenced by
the decrease in expression of both PPAR␥ and adiponectin at
72 h and 96 h after the induction of differentiation. We also
examined the ability of NP to modulate adipogenesis in the
absence of insulin. The preadipocytes were induced to differentiate with normal differentiation medium (MDI) or medium
minus insulin (MD) and harvested 96-h postinduction. As
shown in Fig. 5B, NP was capable of blocking the induction of
both PPAR␥ and adiponectin without insulin present in the
induction mixture. Because cells treated with MD medium
exhibited less differentiation, we used a greater protein concentration than in the normally differentiated cells. To compare
the effect of NP to other gp130 cytokines, 3T3-L1 preadipocytes were induced to differentiate in the presence of NP, as well
as CNTF, CT-1, OSM, and GH. As shown in Fig. 5C, both NP
and OSM greatly attenuated adipogenesis as shown by the
decreased expression of PPAR␥ and adiponectin, whereas
CNTF and CT-1 had no effect on adipocyte marker expression
and was similar to untreated cells. We have previously shown
that CT-1 (33) and CNTF (25) do not inhibit adipogenesis.
These results also confirm recent studies showing that OSM
can inhibit murine (35) and human (36) adipocyte differentiation. It is also known that GH does not affect the adipogenesis of
3T3-L1 cells (37). STAT3 expression does not change during
adipogenesis of murine (38) or human (39) cells and was used as
a loading control.
To demonstrate the specificity of the ability of NP to negatively affect adipogenesis, we investigated whether the attenuation was dose- and time-dependent. In Fig. 6A, 3T3-L1 preadipocytes were induced to differentiate in the presence of NP at
the various doses indicated and harvested 4 days after the
induction of adipogenesis. Cells were treated every 24 h with a
fresh bolus of NP. Although there were no changes in protein
expression at 0.25 nM NP, we observed a decrease in PPAR␥ and
adiponectin expression at 0.5 nM, with the greatest attenuation
of adiponectin at 1 nM and PPAR␥ at 2 nM. In Fig. 6B, 3T3-L1
preadipocytes were induced to differentiate in the presence of
NP at different times post the induction of adipogenesis. Cells
were treated every 24 h with a fresh bolus of NP after their
VOLUME 283 • NUMBER 33 • AUGUST 15, 2008
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FIGURE 6. Neuropoietin inhibits adipogenesis in a dose- and timedependent manner. A, whole cell extracts were prepared from 3T3-L1 preadipocytes or 3T3-L1 cells induced to differentiate in the presence of NP at the
various doses indicated. Cells were treated every 24 h with a fresh bolus of NP.
150 g of each sample were separated by SDS-PAGE, transferred to nitrocellulose, and subjected to Western blot analysis. B, whole cell extracts were
prepared from 3T3-L1 preadipocytes or 3T3-L1 cells induced to differentiate
in the presence of NP (1 nM) at different times post-MDI. Cells were treated
every 24 h with a fresh bolus of NP after their initial treatment. 150 g of each
sample were separated by SDS-PAGE, transferred to nitrocellulose, and subjected to Western blot analysis. Each figure represents an experiment independently performed three times.
FIGURE 5. Neuropoietin attenuates the differentiation of 3T3-L1 adipocytes. A, whole cell extracts were prepared from 3T3-L1 preadipocytes or
3T3-L1 cells induced to differentiate in the presence (⫹) or absence (⫺) of NP
(1 nM). Cells were treated every 24 h with a fresh bolus of NP. 200 g of each
sample were separated by SDS-PAGE, transferred to nitrocellulose, and subjected to Western blot analysis. B, 3T3-L1 cells were induced to differentiate in
the presence (⫹) or absence (⫺) of NP (1 nM). Cells were treated every 24 h
with a fresh bolus of NP. Two samples were induced to differentiate with
normal (MDI) mixture, while the other samples were induced with differentiation mixture minus insulin (MD). Whole cell extracts were harvested 96 h
after the induction of differentiation. 90 g of samples with normal MDI and
200 g of samples with MD media were subjected to Western blot analysis.
This is a representative experiment independently performed three times. C,
whole cell extracts were prepared from 3T3-L1 preadipocytes or 3T3-L1 cells
induced to differentiate in the presence of either NP (1 nM), CNTF (1 nM), CT-1
(1 nM), OSM (1 nM), or GH (0.5 nM). Cells were treated every 24 h with a fresh
bolus of each specific cytokine or growth factor. 200 g of each sample were
separated by SDS-PAGE, transferred to nitrocellulose, and subjected to Western blot analysis. Each figure represents an experiment independently performed at least three times.

initial treatment. Our data indicated that a decrease in
expression of adipogenic markers occurred when NP was
added between 0- and 48-h postinduction. When NP was
added 72- or 96-h postinduction, we did not observe a
change in PPAR␥ or adiponectin levels. The efficacy of NP
AUGUST 15, 2008 • VOLUME 283 • NUMBER 33

was assessed by examining the activation of STAT3 Tyr705,
and STAT3 protein levels were observed to demonstrate
even loading in both experiments.
Because other gp130 cytokines have been reported to have
effects on insulin signaling, we examined how NP affects insulin
action. As shown in Fig. 7A, mature 3T3-L1 adipocytes were
pretreated with NP (⫹) for the times indicated, and then
exposed to an acute 10-min treatment of insulin. As expected, a
10-min insulin treatment resulted in the activation of IRS-1
Tyr896 and Akt Ser473. However, pretreatment with NP prior to
insulin stimulation resulted in a decrease in IRS-1 Tyr896 signaling at 10 min, and we observed this inhibition with each NP
pretreatment. Although we did not see a decrease in Akt Ser473
signaling after the 10-min NP pretreatment, we observed a significant attenuation in Akt activation after 2 h with NP pretreatment. The efficacy of the NP was demonstrated by confirming the activation of STAT3 Tyr705. A longer exposure of
the film revealed lower levels of STAT3 phosphorylation following longer NP pretreatment. ERK (MAPK) protein levels
were examined to demonstrate even loading.
JOURNAL OF BIOLOGICAL CHEMISTRY
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FIGURE 8. Neuropoietin attenuates insulin signaling in adipose tissue in
vivo. 7-week old male C57B1/6J mice were given an intraperitoneal injection
of either vehicle (saline) control, or insulin (5 units/kg), with or without a
pre-injection of NP (0.20 g/g animal). In each individual experiment, two
animals were used for each condition. The mice were treated with insulin
alone or following either a 30- or 90-min NP pretreatment. After the mice
were injected with insulin for 15 min, they were sacrificed, and epididymal fat
pads (A) and retroperitoneal fat pads (B) were immediately removed and frozen in liquid nitrogen. 250 g (epididymal) or 150 g (retroperitoneal) of each
tissue extract were separated by SDS-PAGE, transferred to nitrocellulose, and
subjected to Western blot analysis. Each figure represents an experiment
independently performed twice on separate groups of mice.

FIGURE 7. Neuropoietin inhibits insulin signaling and insulin-stimulated
glucose uptake. A, fully differentiated 3T3-L1 adipocytes were pre-treated
with NP (1 nM) for the times indicated. Next, the cells were then treated for 10
min with insulin (50 nM). Following treatment, whole cell extracts were prepared, and 100 g of each sample were separated by SDS-PAGE, transferred
to nitrocellulose, and subjected to Western blot analysis. This is a representative experiment independently performed three times. B, confluent 3T3-L1
preadipocytes were pretreated with NP (1 nM) for the times indicated. Next,
the cells were treated for 10 min with insulin (50 nM). Following the treatment, whole cell extracts were prepared, and 120 g of each sample were
separated by SDS-PAGE, transferred to nitrocellulose, and subjected to
Western blot analysis. This is a representative experiment independently
performed three times. C, fully differentiated 3T3-L1 adipocytes were
serum-deprived for 2 h and then treated with NP (1 nM) for 6 h. After
pretreatment, cells were stimulated with insulin (50 nM) for 10 min. Glucose uptake was initiated by addition of 2-[3H]deoxyglucose. The glucose
uptake values shown represent the mean ⫾ S.E. of triplicate determinations from four independent experiments.

Because NP negatively affects insulin signaling in adipocytes,
we examined the effects of NP on insulin signaling in preadipocytes. As shown in Fig. 7B, confluent 3T3-L1 preadipocytes
were pretreated with NP (⫹) for the times indicated, and then
exposed to an acute 10-min treatment of insulin. Although a
10-min insulin treatment resulted in the activation of IRS-1
Tyr896, pretreatment with NP for various times prior to insulin
stimulation resulted in a decrease in IRS-1 Tyr896 phosphorylation. The efficacy of NP was demonstrated by observing the
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activation of STAT3 Tyr705. ERK (MAPK) protein levels were
examined to demonstrate even loading.
Because we observed a decrease in insulin signaling with NP
pretreatment, we examined the ability of NP to regulate insulinstimulated glucose uptake in 3T3-L1 adipocytes. As shown in
Fig. 7C, a 10-min treatment with insulin resulted in a nearly
5-fold increase in glucose uptake as compared with the vehicletreated cells. However, following a 6-h pretreatment with NP,
we observed a substantial decrease in insulin-stimulated glucose uptake compared with controls. The lack of insulin-stimulated uptake was not due to a significant increase in basal
glucose uptake.
The data in Fig. 7 clearly indicated that NP negatively affects
insulin signaling in adipocytes in vitro; therefore, we examined
the ability of NP to attenuate insulin signaling in adipose tissue
in vivo. C57B1/6J mice were injected with either vehicle (saline)
or insulin, with or without a pre-injection of NP. The doses of
NP used were based on doses of CNTF that are known to correct obesity and diabetes and result in a reduction of body fat in
mice (15, 16). The mice were treated for 15 min with insulin
alone or following either a 30- or 90-min NP pretreatment. As
shown in Fig. 8, a 15-min insulin treatment resulted in the activation of Akt Ser473. Although we did not see a decrease in Akt
Ser473 signaling after the 30-min NP pretreatment, we observed
a significant attenuation in Akt activation after 1.5 h with each
NP pretreatment in both the epididymal (Fig. 8A) and retroperitoneal (Fig. 8B) adipose tissues. The efficacy of NP was assessed
by the activation of STAT3 Tyr705, and ERK (MAPK) protein
levels were observed to demonstrate even loading.
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DISCUSSION
Because of recent studies that implicate gp130 cytokines,
specifically CNTF, as potential therapeutic targets for obesity
(22), we investigated the actions of NP in adipocytes both in
vitro and in vivo. Even though sequence analysis suggests that
the np gene has evolved into a pseudogene in humans (22), we
hypothesized that NP, due to similar functional roles with
CNTF, could induce anti-obesogenic effects and be considered
a potential therapeutic treatment. Although NP signals via the
same tripartite receptor complex as CNTF, our findings demonstrate both similar and opposing roles for NP compared with
CNTF. In adipocytes, both NP and CNTF activate STAT3
Tyr705 in vivo and in vitro and induce the nuclear translocation
of STAT3 but not STATs 1 and 5A in vitro. Our studies also
indicate that NP treatment, like CNTF, resulted in ERK 1 and 2
activation in vivo (6). As shown in Fig. 3, NP and CNTF (33) are
also alike in their ability to induce SOCS-3 mRNA in 3T3-L1
adipocytes. SOCS-3 proteins have been shown to play a role in
both leptin resistance (40) and insulin resistance (41). Interestingly, SOCS-3 is induced by all known gp130 cytokines (32, 33,
42– 47), as well as additional hormones, including insulin (48),
growth hormone (49), and leptin (50). However, many inducers
of SOCS-3, including CTNF, do not induce insulin resistance. It
is striking that so many cytokines, in addition to NP and CNTF
result in the activation of STAT3, ERK 1 and 2 and SOCS-3, yet
the action of these cytokines have different responses despite
the activation of the same signaling proteins.
Although our observations indicated that NP induced the
same signaling proteins as CNTF in adipocytes, we observed
different effects of NP, as compared with CNTF, on both adipogenesis and insulin action. Our results demonstrated that NP
can inhibit adipogenesis in a dose- and time-dependent manner
in 3T3-L1 cells, whereas CNTF does not attenuate adipogenesis
in this model system (25). The different effects do not appear to
be due to altered levels of STAT3 activation, as equivalent levels
of NP and CNTF results in similar activation of STAT3 (data
not shown). CT-1, LIF, and OSM activate STAT3 in a manner
equivalent to NP (Fig. 1), but only OSM and NP inhibit differentiation (Fig. 5B). In addition, the ability of NP to block adipogenesis does not seem to be dependent on the presence of insulin or the negative effects on insulin action. Although NP can
attenuate insulin signaling in both preadipocytes (Fig. 7B) and
adipocytes (Fig. 7A), our data indicate that NP could inhibit
adipocyte differentiation in the absence of insulin (Fig. 5B).
Of all the gp130 cytokines, NP is the most structurally and functionally related to CNTF and CT-1, yet, neither CNTF nor
CT-1 attenuate adipogenesis (25, 33). These observations suggest the specificity of these gp130 cytokines to modulate adipocyte differentiation involves more than their ability to activate
STAT3 and ERK and induce SOCS-3 expression and indicate
that NP possesses unique signaling abilities that differ from
CNTF despite use of the same receptor complex.
Despite the presence of CNTFR␣ in skeletal muscle (25, 51),
our results demonstrate that acute NP treatment failed to activate STAT3 Tyr705 in skeletal muscle in vivo, in contrast to
CNTF which induced STAT3 Tyr705 phosphorylation in the
skeletal muscle of rodents (25). In addition, CNTF has been
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shown to increase fat oxidation and reduce insulin resistance
via an AMP-activated protein kinase (AMPK)-dependent
mechanism in skeletal muscle (11). It is possible that NP could
also mediate signal transduction in skeletal muscle via other
signaling pathways that are independent of the JAK/STAT pathway, as we did not test this hypothesis in our experiments. Nonetheless, our studies indicate that NP and CNTF have very divergent actions not only in adipose tissue, but also in skeletal muscle.
Importantly, our studies indicate that NP treatment not only
attenuates insulin signaling in vitro, as demonstrated by
decreased activation of both IRS-1 Tyr896 and Akt Ser473, but
also in vivo, as evidenced by the reduction in Akt activation. In
comparison, CNTF treatment was shown to act synergistically
with insulin to increase the activation of both IRS-1 Tyr896 and
Akt Ser473 in cultured adipocytes (25) and in vivo studies demonstrated that CNTF could improve insulin sensitivity in dietinduced and genetic models of obesity (11). In addition to our
findings that NP negatively regulates insulin signaling proteins,
we demonstrated that NP treatment impaired insulin-stimulated glucose uptake in cultured adipocytes. Because CNTF
treatment of cultured adipocytes did not result in insulin resistance (25), these results clearly indicate significant and opposing
roles between NP and CNTF.
This represents the first study to examine the role of NP in
adipocytes. Interestingly, we observed distinct responses
between NP and CNTF in adipocytes and skeletal muscle
despite studies which showed that both of these cytokines act
through the same signaling receptor complex (20, 22). In summary, our findings indicate that NP can affect adipogenesis and
insulin sensitivity in fat cells both in vitro and in vivo. Based on
our present data, NP, unlike CNTF, is not a suitable anti-obesity
therapeutic because it inhibits insulin action and negatively
affects glucose uptake in adipocytes.
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